Physician profile
Ying Ning
NPI 1366970618
$619.04
in general payments reported to CMS, 2019-2025
19 companies · $43.25 in 2025
The $43.25 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205 · 2020: $101 · 2021: $86.39 · 2022: $126 · 2023: $57.42 · 2025: $43.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $57.42 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $57.42 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $158.08 | 2019-2025 | Enhertu |
| Incyte Corporation | $60.55 | 2022-2023 | Jakafi |
| Pfizer INC. | $50.48 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.94 | 2021-2022 | |
| Sobi, INC | $35.04 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.14 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $28.44 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $24.19 | 2019 | |
| Abbvie INC. | $22.91 | 2019 | |
| Daiichi Sankyo INC. | $21.55 | 2022 | |
| Viiv Healthcare Company | $20.97 | 2019 | |
| Genzyme Corporation | $17.22 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.98 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.17 | 2020 | |
| Alnylam Pharmaceuticals INC. | $15.75 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $14.33 | 2021 | |
| Celgene Corporation | $12.90 | 2023 | Pomalyst |
| Amgen INC. | $11.81 | 2021 | |
| Glaxosmithkline, LLC. | $11.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ying Ning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.